The Second Century of the Antibody. Molecular Perspectives in Regulation, Pathophysiology, and Therapeutic Applications

Overview

Journal West J Med

Specialty General Medicine

Date 1992 Aug 1

PMID 1441467

Authors

J Braun

A Saxon

R Wall

S L Morrison

Affiliations

Soon will be listed here.

Abstract

The modern age of immunology began in 1890 with the discovery of antibodies as a major component of protective immunity. The 2nd century of the antibody begins with a focus on the molecular physiology and pathophysiology of immunoglobulin production. Numerous human variable-region antibody genes have been identified through advances in molecular cloning and anti-variable-region monoclonal antibodies. Some of these variable-region genes are now known to be involved in specific stages of B-lymphocyte differentiation and immune development. This connection has yielded new insights into the pathogenesis of immune dyscrasias and lymphoid neoplasia; common variable immunodeficiency and cryoglobulinemia are highlighted here. The molecular regulation of immunoglobulin expression suggests new targets for pathogenesis and clinical intervention. Finally, genetically engineered antibodies offer novel opportunities for diagnostic and therapeutic applications.

References

Saxon A, Giorgi J, Sherr E, Kagan J . Failure of B cells in common variable immunodeficiency to transit from proliferation to differentiation is associated with altered B cell surface-molecule display. J Allergy Clin Immunol. 1989; 84(1):44-55. DOI: 10.1016/0091-6749(89)90177-2. View

Tosato G, Gerrard T, Goldman N, Pike S . Stimulation of EBV-activated human B cells by monocytes and monocyte products. Role of IFN-beta 2/B cell stimulatory factor 2/IL-6. J Immunol. 1988; 140(12):4329-36. View

Duncan A, Woof J, Partridge L, Burton D, Winter G . Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature. 1988; 332(6164):563-4. DOI: 10.1038/332563a0. View

Said J . AIDS-related lymphadenopathies. Semin Diagn Pathol. 1988; 5(4):365-75. View

Alt F, Blackwell T, DePinho R, Reth M, Yancopoulos G . Regulation of genome rearrangement events during lymphocyte differentiation. Immunol Rev. 1986; 89:5-30. DOI: 10.1111/j.1600-065x.1986.tb01470.x. View

Schroeder Jr H, Hillson J, Perlmutter R . Early restriction of the human antibody repertoire. Science. 1987; 238(4828):791-3. DOI: 10.1126/science.3118465. View

Kipps T, Tomhave E, Chen P, Carson D . Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy. J Exp Med. 1988; 167(3):840-52. PMC: 2188892. DOI: 10.1084/jem.167.3.840. View

Briskin M, Kuwabara M, Sigman D, Wall R . Induction of kappa transcription by interferon-gamma without activation of NF-kappa B. Science. 1988; 242(4881):1036-7. DOI: 10.1126/science.3143155. View

Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K . The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med. 1988; 167(2):332-44. PMC: 2188837. DOI: 10.1084/jem.167.2.332. View

10.

Sherr E, Adelman D, Saxon A, GILLY M, Wall R, Sidell N . Retinoic acid induces the differentiation of B cell hybridomas from patients with common variable immunodeficiency. J Exp Med. 1988; 168(1):55-71. PMC: 2189392. DOI: 10.1084/jem.168.1.55. View

11.

Chien M, Yokoyama W, Ashman R . Mitogen-stimulated phospholipid synthesis in normal and immune-deficient human B cells. J Immunol. 1986; 136(8):2844-50. View

12.

Van Damme J, Opdenakker G, Simpson R, Rubira M, Cayphas S, Vink A . Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med. 1987; 165(3):914-9. PMC: 2188297. DOI: 10.1084/jem.165.3.914. View

13.

Williams G, Neuberger M . Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment. Gene. 1986; 43(3):319-24. DOI: 10.1016/0378-1119(86)90223-4. View

14.

Whitlock C, Denis K, Robertson D, Witte O . In vitro analysis of murine B-cell development. Annu Rev Immunol. 1985; 3:213-35. DOI: 10.1146/annurev.iy.03.040185.001241. View

15.

Kishimoto T . Factors affecting B-cell growth and differentiation. Annu Rev Immunol. 1985; 3:133-57. DOI: 10.1146/annurev.iy.03.040185.001025. View

16.

Wu L, Lawton A, Cooper M . Differentiation capacity of cultured B lymphocytes from immunodeficient patients. J Clin Invest. 1973; 52(12):3180-9. PMC: 302594. DOI: 10.1172/JCI107518. View

17.

Neuberger M, Williams G, Fox R . Recombinant antibodies possessing novel effector functions. Nature. 1984; 312(5995):604-8. DOI: 10.1038/312604a0. View

18.

Rosen F, Cooper M, Wedgwood R . The primary immunodeficiencies (1). N Engl J Med. 1984; 311(4):235-42. DOI: 10.1056/NEJM198407263110406. View

19.

Tonegawa S . Somatic generation of antibody diversity. Nature. 1983; 302(5909):575-81. DOI: 10.1038/302575a0. View

20.

Denis K, Wall R, Saxon A . Human-human B cell hybridomas from in vitro stimulated lymphocytes of patients with common variable immunodeficiency. J Immunol. 1983; 131(5):2273-8. View